October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…
October 19, 2025 08:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) --…
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…
Dubai, UAE , Oct. 18, 2025 (GLOBE NEWSWIRE) -- The DeFi market continues to evolve rapidly, and new protocols are…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
HANGZHOU, China, Oct. 13, 2025 /PRNewswire/ -- Jiuzi Holdings, Inc. (NASDAQ: JZXN, hereinafter referred to as the "Company") today elaborated…
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a…